Critical Survey: Trillium Therapeutics (TRIL) and Medgenics (GNMX)

Trillium Therapeutics (NASDAQ: TRIL) and Medgenics (NASDAQ:GNMX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.

Volatility & Risk

Trillium Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Medgenics has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.

Earnings and Valuation

This table compares Trillium Therapeutics and Medgenics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Trillium Therapeutics N/A N/A -$23.96 million ($3.79) -1.87
Medgenics N/A N/A -$41.90 million ($1.13) -2.04

Medgenics is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Trillium Therapeutics and Medgenics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trillium Therapeutics N/A -248.39% -65.21%
Medgenics N/A -163.88% -130.14%

Insider & Institutional Ownership

45.5% of Trillium Therapeutics shares are held by institutional investors. Comparatively, 16.6% of Medgenics shares are held by institutional investors. 15.2% of Medgenics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Trillium Therapeutics and Medgenics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trillium Therapeutics 0 0 3 0 3.00
Medgenics 0 1 1 0 2.50

Trillium Therapeutics presently has a consensus target price of $14.00, suggesting a potential upside of 97.18%. Medgenics has a consensus target price of $4.25, suggesting a potential upside of 84.78%. Given Trillium Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Trillium Therapeutics is more favorable than Medgenics.

Summary

Trillium Therapeutics beats Medgenics on 8 of the 11 factors compared between the two stocks.

About Trillium Therapeutics

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

About Medgenics

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit